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Abstract 
 
This article updates the guidance published in 2015 for authors submitting papers to British Journal 
of Pharmacology (BJP) (Curtis et al., 2015) and is intended to provide the rubric for peer review. 
Thus, it is directed towards authors, reviewers and editors. Explanations for many of the 
requirements were outlined previously and are not restated here. The new guidelines are intended 
to replace those published previously.  The guidelines have been simplified for ease of 
understanding by authors, to make it more straightforward for peer reviewers to check compliance, 
and to facilitate the curation of the journal’s efforts to improve standards. 
 
Introduction 
 
The aim of this update is to: 
• share lessons learnt during the two years since the implementation of our guidelines  
• update guidance on requirements for design and analysis where our views have 
changed/advanced since 2015  
• include advice and guidance on additional areas of design and analysis pertinent to 
pharmacology research not discussed in the previous version 
• make the journal requirements clearer and easier to curate.  
 
The main lesson learnt (from internal journal audit) that we may now share is that the guidelines 
that have been journal requirements since 2015 are not being routinely followed by authors and 
this is being missed during the peer review process. This ‘non-compliance’ is not unique to BJP and 
is a phenomenon experienced by many other journals. Indeed, Nature recently reported that when 
guidelines are introduced, ‘author compliance can be an issue’ (anonymous 2017). There are 
certain topics that continue to be particularly problematic (e.g. normalisation, transformation and 
inappropriate use of parametric statistics). Our solution is to make two key changes. We have 
updated and simplified our list of requirements for authors and we have created a flow chart 
explaining how peer review may be accomplished efficiently. We also include figures to illustrate 
key aspects of good and inappropriate practice in data acquisition and processing. In doing this, we 
facilitate one of the key aims of the British Pharmacological Society (BPS) which is to support the 
improved reporting and ‘transparency’ of experimental work. Finally, we provide new guidance on 
certain more nuanced matters, including the handling of outliers in datasets.  
 
We note that this new guidance is entirely focused on design and analysis. Previous guidance in our 
journal discussed requirements for design and analysis with other important, but distinct, issues 
concerning the use of animals and experimental ethics (e.g. ARRIVE). In hindsight, we feel that our 
discussion  of the two separate issues together may have resulted in a lack of clarity, contributing to 
the inadequate compliance . Guidance on ethical animal experimentation is published elsewhere 
(McGrath and Lilley 2015), and will be updated separately in 2018. 
 
In order to facilitate implementation of the guidelines, journal instructions now require that every 
paper should contain a data and statistical analysis sub-section within the Methods and full detail of 
design within each protocol described. 
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Key points of the updated guidance 
 
1. Group sizes should be sufficient to permit any statistical analysis to be meaningful. BJP has set 5 
as the minimum ‘n’ required for datasets subjected to statistical analysis.  Designing a study to 
compare groups with n<5 is permissible if carefully justified (e.g. shortage of sample 
availability), but any data set containing groups of n<5 must not be subjected to statistical 
analysis and findings must be labelled as ‘exploratory’ or ‘preliminary’. Any such data should 
constitute only a small proportion of the paper. We note that group size is the number of 
independent values, so one sample run 5 times is n=1, not n=5. We note that it is common for 
authors to run 3 samples ‘in quintuplicate’, then analyse the data with statistical analysis as if it 
were n=15 rather than n=3. This is not acceptable for publication in BJP. 
2. Studies should be designed to generate groups of equal size, using randomisation and blinded 
analysis where possible (with credible justification if not possible). If group sizes become 
unequal during a study owing to technical failure this must be explained in the Results. 
However, we encourage replacement of lost values according to defined criteria. Clear 
statements on all these features must be made in the Methods. 
3. After ANOVA, post hoc tests may be run only if F achieves the necessary level of statistical 
significance (i.e. P<0.05) and there is no significant variance inhomogeneity. Adherence must be 
stated in the Methods (‘data were analysed by ANOVA followed by Tukey’s test’ is not 
sufficient). If these criteria are not met, a post hoc test should not be run (even if the software 
permits this, which it may).  
4. In Methods, approaches used to reduce unwanted sources of variation by data normalisation 
(which means the correction of test values to baseline or control group values) or to generate  
normal (Gaussian) data (e.g., by log-transformation) must be justifiable and explained. 
Normalisation or transformation can affect the appropriateness of the chosen statistical 
method. For example, normalisation to matched controls will generate a control mean of 1 and 
no SEM, meaning that parametric tests (ANOVA, etc.) cannot be used (only non-parametric 
analysis is acceptable). Any dataset where one group has no SEM (common in western blot 
analysis) must be analysed by non-parametric statistics. Following data transformation, the Y 
axis is often labelled incorrectly (it should be ‘fold matched control values’, or ‘fold mean of the 
controls’, and not ‘fold control’).  
5. When comparing groups, a level of probability (P) deemed to constitute the threshold for 
statistical significance (typically in pharmacology this is P<0.05) should be defined in Methods, 
and not varied later in Results (by presentation of multiple levels of significance). 
6. Outliers are data values that diverge from the central tendency. An outlier may be a rogue value 
or part of the innate data distribution. Several aspects of the data distribution may need to be 
considered before an investigator can decide how to deal with outliers. It is possible to define 
an outlier in a control population, but only if a large number of control values are available for 
evaluation. Outliers should therefore be included in data analysis and presentation unless a 
predefined and defensible set of exclusion criteria can be generated and applied.  
 
The peer review process  
 
We expect BJP papers to be written in such a way that the basic requirements of design and 
analysis are described clearly by authors, and can be checked in peer review. To improve this 
process, we have prepared a summary flow chart of how peer reviewers may quickly triage the key 
areas and check for compliance with BJP’s core requirements. At the same time this flow chart 
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explains to authors what BJP expects from them. The triage scheme (Figure 1) should be used by 
authors and those involved in peer review, with the more detailed updated guidance (above) used 
as a reference to clarify any uncertainty. 
 
 
Figure 1. This flow chart describes how triage of the design and analysis aspects of a paper may be checked 
by authors and by peer reviewers. 
 
 
 
Areas of particular concern that require renewed vigilance 
 
Many of the key issues in the flowchart (Figure 1) will be simple to address. Authors must make 
statements about each listed item in their Methods. In recently submitted studies that do not 
currently comply with our requirements, it is often the case that we find all of the following: a lack 
of randomization and blinding, unequal group sizes, and statistical analysis applied when n is <5. 
Together, these render a paper fundamentally flawed and, as Figure 1 indicates, this will now result 
in triage rejection.  In view of this we conducted an audit of the present general compliance with 
the guidance introduced in 2015. Table 1 illustrates it has not succeeded as we had hoped. 
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Below we discuss specific matters illustrated in Table 1. 
 
Data normalisation, transformation, statistical analysis and presentation 
 
One important matter concerns normalisation (e.g., correction of values to baseline to reduce 
variation), and data transformation to generate data necessary for the application of statistics that 
depend upon a ‘normal’ (Gaussian) distribution. With respect to normalisation, Figure 2, as an 
Table	1.	Many	papers	published	in	British	Journal	of	Pharmacology	do	not 	adhere	to	all	the	journal's	guidance
All	N=5+ Equal		N
Randomized	
statement
Blind	
statement
P	
constant
correct		
Y	axis	
label
Correct	
post	hoc
0 0 0 0 0 0 1
0 0 0 0 1 1 1
0 0 0 0 1 0 1
1 0 0 0 1 1 1
0 1 0 0 1 1 1
1 0 1 1 1 0 1
1 1 1 1 1 1 1
1 0 1 1 1 1 1
1 0 1 0 1 0 1
1 1 1 0 1 1 1
0 0 0 0 1 1 1
1 0 0 0 1 1 1
1 0 0 1 0 1 1
1 0 0 0 0 1 0
1 1 0 0 0 1 1
1 1 1 0 1 1 1
1 0 1 1 1 0 1
1 0 1 1 1 1 1
1 1 0 1 1 0 0
1 0 1 1 1 0 0
1 0 0 0 1 0 0
1 1 0 0 1 0 0
0 0 1 1 1 0 0
1 0 0 0 1 0 0
1 0 0 0 1 0 0
0 1 0 0 1 0 1
%	compliance 73 31 38 35 85 50 69
The	data	above	summarises	papers	in	three	issues	of	British	Journal	of	Pharmacology	published	at	least	6
	months	after	the	publication	of	the	journal's	original	guidance	on	design	and	analysis.	The	issues	analysed	were	
selected	at	random	and	are	representative.	The	articles	are	the	entire	set	of	original	research	papers	published
in	each	of	the	three	issues	sampled.	Papers	were	judged	compliant	(1)	or	not	(0).	Papers	not	stating	whether	the	study
	was	blinded	or	randomised	or	not	were	assumed	to	be	non-compliant.	'Correct	Y	axis	label'	means	that	for	normalised	
data,	if	the	control	mean	is	1	with	no	SEM	the	label	should	be	'fold	matched	controls',	whereas	if	the	control	
mean	has	an	s.e.mean	the	Y	axis	label	should	be	'fold	control	mean'	(especially	relevant	to	Western	blot	and	qRT-PCR	data).	
	'Correct	post	hoc	test'	means	that	parametric	tests	were	used	only	when	the	control	mean	has	a	variance,
or	there	is	no	obvious	violation	of	ANOVA	(e.g.,	post	hoc	tests	done	when	the	controls	have	no	variance	or	a
sequence	of	groups'	SEMs	that	are	proportional	to	the	mean).	Given	that	all	the	papers	were	found	to	cite	
the	previous	guidance	document,	and	in	doing	so	made	a	declaration	of	concordance	with	the	guidelines.	
We	would	expect	the	%	compliance	for	each	item	to	be	100%.	The	fact	it	is	not	explains	why	we	have	written	this	article.
7 
 
example, shows two different acceptable ways of analysing and presenting data that, for reasons 
the author should explain in Methods, are normalised to control (a common procedure in Western 
blot analysis and electrophysiology studies). It is interesting, and not well recognised, that the data 
normalisation approach (panel B) is not actually a true normalisation and is, in fact, simply a 
rescaling of the Y axis of the raw data (see legend).  The important difference between the two 
approaches, however, is that the control in panel B has a standard error whilst the control in panel 
A does not.  Both are acceptable forms of data presentation for BJP, however the Y axis label and 
the statistical tests that should be applied are different. 
 
 
 
 
 
Figure 2. Parametric versus non-parametric. Individual data points (circles), mean values (x) and SEM values 
are shown. In panel A two datasets derived from an analysis (e.g. western blotting) where each drug 
experiment included a control. When the data are from different sources, then a common practice is for 
each drug value to be normalised to each matched control value. This means that the control mean is 1, and 
there is no variance in the control. The correct way to analyse these data is using a non-parametric statistical 
test, and the correct label for the Y axis is ‘fold matched control’. Because analysis is non-parametric, it is 
misleading to show the parameter SEM. In panel B, each control and each drug value has been ‘normalised’ 
to the mean value of the control group (mean values shown as x). In other words, each raw value has been 
divided by the value of the mean of the control values. This generates a Gaussian dataset that can be 
analysed by parametric statistics (provided the variance is similar in the two groups – a t test may falsely 
identify a nonsignificant difference if the two SEM values differ greatly – see Figure 3) and, if so, it is 
appropriate to show the SEM (error bars in the figure). However, there is actually no benefit in making this 
transformation since the ratio between each mean and each SEM is the same as the equivalent ratios for the 
raw data. In other words, this ‘transformation’ is identical to a relabelling or rescaling of the Y axis from the 
absolute raw values to new values for which the control mean value is relabelled as ‘1’. This has no effect on 
the ability of the parametric statistical test to detect a significant difference. However, readers have a 
tendency to make ‘eyeball’ comparisons between normalised datasets in the same paper or indeed from one 
paper to the next, and this may lead to false inferences. Thus, use of either the normalisation shown in panel 
A, or presentation of the raw data (in units that may be arbitrary if this is the case) is preferred, although we 
acknowledge that for quantitative PCR the ‘transformation’ depicted in panel B represents common practice 
at the present time. We also remind authors to ensure that whatever normalisation is chosen, the Y axis is 
labelled correctly (fold control is not correct) and the appropriate type of statistical test is used. 
 
With respect to data transformation, our audit has revealed two key issues: 
• The first is that data that are not Gaussian distributed are often subjected to parametric 
statistical analysis (t tests, ANOVA and post hoc tests that account for multiple groups such as 
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Tukey). This should not happen, and such data should be subjected to non-parametric tests such as 
the Mann Whitney U test.   
• The second key point is that a data transformation is underused. It can be helpful for 
analysis because it can convert data to fit a Gaussian distribution. In this context, in pharmacology, 
we are familiar with log-Gaussian datasets and recommend log transformation when it can be 
justified. The need is much easier to identify than one might imagine: if the SEM increases in size in 
proportion to the size of the mean the data are likely to be log-Gaussian distributed, and the 
benefits (and indeed the necessity) of log transformation are shown in Figure 3. 
 
 
 
Figure 3. Data Transformation. Individual data points (circles), mean values (x) and SEM values are shown. In 
panel A, owing to the large variance in the drug group, a t test identifies the two groups as not significantly 
different. However, closer examination shows this to be a false inference. The individual data values are not 
equally distributed around the arithmetic mean, and an arithmetic SEM should not be used to summarise 
the distribution. It is possible to analyse the data shown in panel A using a non-parametric statistical test 
(such as a U test), but non-parametric tests are less powerful than parametric tests and their use can result 
in false negative findings. In panel B, the same data are log transformed and the Y axis uses the log scale. 
Here the SEM is no longer proportional to the mean, and the values are Gaussian distributed. It is 
appropriate to show the SEM. A t test correctly identifies a statistically significant difference between 
groups. This transformation unsettles some investigators as it appears to be a manipulation of data. 
However, in nature, many variables are log-Gaussian distributed. Sound (decibels) and acidity (pH) are units 
on a log scale, used because the variable is log Gaussian. In pharmacology the pA2, and even the relationship 
between a response and a drug concentration are log-Gaussian. This is why we express agonist and 
antagonist “affinity” values as pKA and pKB, respectively not KA and KB similarly so for EC50 or IC50 that should 
be expressed as pEC50 and pIC50. It should be no surprise that many other variables in biology are log-
Gaussian distributed (for example the number of ectopic beats occurring in experimental myocardial 
infarction). The key issue here is that authors and peer reviewers should look at figures to ensure that data 
like those in the left-hand part of the figure are not included in a paper – if they are the data should be re-
analysed.  
 
Group sizes – what is a group size and what is a group? 
 
We have become aware of inconsistencies in how authors analyse data in terms of how the group 
size is defined. The first question to address is ‘what is a group’? We alluded above to a group being 
comprised of independent samples. But what is an independent sample?  For BJP, ‘independent’ 
signifies that the sample represents a bias-free representation of the population. Thus, five cells 
from one mouse given the same treatment is not n=5, and these five cells should be regarded as 
technical replicates, with n=1 consensus value taken forward into statistical analysis. For such cell 
work, studies are often designed to include technical replicates because it is quick and easy to do so 
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and it helps provide confidence that the technique and equipment are working. Nevertheless, it 
could also be argued that for in vivo experimentation datasets derived from five mice housed in the 
same cage and given the same treatment should also be treated as technical replicates to provide 
n=1. Such scenarios should not occur in well-designed studies.  However, we note that there are 
occasions when n=5 mice housed in the same cage should not be treated as n=1. A full explanation 
of why this might be the case should be given in the Methods. In sum we expect statistical analysis 
to be undertaken on groups whose size is defined by the number of samples that are demonstrably 
independent, i.e., generated from a study with a randomised design.  
 
Regarding minimum group sizes, we have stated that a good rule of thumb is to add 50% to the n 
determined by power analysis, in order to avoid under powering. This is arbitrary guidance. It is 
based on the fact that power analysis defines the minimum group size to obtain significance that is 
reliable 50% of the time, and therefore it makes sense to add 50% to the group. We may revisit this 
recommendation in the future. 
 
Experimental outliers 
 
We have introduced new guidelines on how to manage experimental outliers, which are defined as 
values that digress from the central tendency (or ‘central location’). There are several issues that 
need to be considered before an investigator can decide how to deal with outliers. First, how does 
one identify an outlier? With small group sizes (n<12) this may be impossible. It is feasible to define 
an outlier in a control population as a value that lies outside a defined range, but only if the 
distribution of values is well defined. This requires a very large group size.  
 
If it is possible to define an outlier then the next question to address is: why is a value an outlier? 
The reason may be that the value is false, contaminated or in some other way incorrect. On the 
other hand, it may be correct, and the result of a natural wide spread of data, or even a bimodal 
distribution of data. The latter would arise, for example, if one were to analyse readouts in a 
population that expresses a polymorphism, such as deficiency in acetylcholinesterase in a small 
section of the human population. Excluding such outlier values or subjects is justified only in an 
experiment defined to be relevant only to the larger population, for instance, in the 
acetylcholinesterase example, those with typical enzyme activity. It is therefore essential to know 
what the explanation is for an outlier, since it is inappropriate to exclude correct values just 
because they alter the data distribution. 
 
Genuinely false values should be excluded from a sample, but this must be done using predefined 
criteria. Using a formula based on the standard deviation is one. A number of others are available in 
routinely used statistical packages but their use can be problematic (Leys et al., 2013). Alternatively, 
one may use an arbitrary limit of acceptability (e.g. to exclude animals whose surgery has lowered 
blood pressure to below a value appropriate for testing drug effects especially, in this example, 
effects on blood pressure). This approach is acceptable to BJP, but exclusion criteria should be 
defined beforehand and applied on blinded data to avoid bias. Exclusion criteria should be fully 
described in Methods. 
 
With a novel type of study (i.e. where there are no historical controls and database of records with 
which to consult) it is essential to ensure unbiased quality control, which means undertaking 
preliminary studies in order to allow generation of arbitrary exclusion criteria, keeping in mind that 
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the justification cannot be ‘scientific’, merely pragmatic (to ensure that data can be analysed 
statistically without the need for onerously large group sizes). It is wise to revisit any criteria as new 
data emerge. We encourage authors to include any data that updates their previous exclusion 
criteria within manuscripts. 
 
When it is impossible to justify reasons for exclusion of data, the best solution is to include all data 
including any apparent ‘outliers’ and ensure group sizes are large (increased by 50% from the value 
determined by power analysis is advisable). When inclusion of outliers is decided to be the best 
option, this may generate non-Gaussian datasets. These can be modified by use of transformations 
or process using non-parametric statistical tests, as discussed above.  
 
In summary, outliers should be included in a data set unless a predefined and defensible set of 
exclusion criteria can be generated and applied. 
 
Statistical significance 
 
The majority of papers published in BJP contain data sets where several test groups are compared 
with a control group in order to examine whether a drug has ‘an effect’. In this context statistics are 
used to inform a binary decision about whether there is an effect or not. BJP continues with the 
policy that authors must define what level of P they consider to constitute statistical significance 
within the Methods section of the paper. Authors may choose a more stringent P threshold than 
the current norm of P<0.05, but this must not be changed from one part of a manuscript to 
another.  
 
Statistical analysis does not guarantee that a finding is necessarily correct, and we will allow an 
author the right to argue that a false positive or a false negative finding may have been generated. 
This issue is particularly relevant to variables of secondary interest. Clearly group size should be 
determined a priori such that an expected effect on the variable of primary interest can easily be 
detected using the predefined P threshold (we refer readers again to our advice to undertake 
power analysis and add another 50% to the group size). However, this may mean that the group 
sizes are insufficient for reliable detection of effects on secondary and subsidiary variables. It is the 
responsibility of the author to explain this in the paper, especially if they wish to argue that an 
apparent lack of difference was due to a type 2 error (false negative).  We additionally encourage 
authors to be aware that the calculated P value is almost always bigger than it seems (‘less 
significant’) owing to the false discovery rate which is one reason why some investigators argue 
that most (rather than just some) research findings are false (Colquhoun 2014; Begley 2013; Begley 
& Ioannidis 2015).  
 
 
Flexibility and pilot data 
 
As noted in the detailed guidance (above), we accept that a sample may be lost due to a technical 
problem, and that blinding the data analysis may be compromised owing to a very large i.e. 
obvious, drug effect. In such scenarios authors may easily explain why their study falls short in 
these aspects, and we expect editors to accept a good explanation. Separately, it may be useful to 
include a small amount of pilot data (for example the high throughput data on tens or hundreds of 
compounds used in selecting candidates for full investigation) derived from experiments that may 
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not be blinded, randomized or fit for statistical analysis, and we encourage authors to do so, with 
the data presented (without P values) in Methods in a sub-section headed Pilot Study. 
 
Conclusions 
 
Here we have updated and simplified the requirements of BJP for experimental design and analysis. 
The objective is to facilitate manuscript preparation, and help peer review become more consistent 
and transparent, generating research articles whose data are more likely to be reproducible.  
 
The caveat is that there is no panacea as implementation of any process is entirely dependent on 
stakeholders engaging with it. If guidance is too onerous, too detailed or ambiguous, or presented 
as optional (‘best practice’) it is likely to fail. If authors ignore the guidance and peer review fails to 
recognise this, we will make no progress. Keeping guidance and the process of its implementation 
simple has a better chance of success than elaboration of complex and detailed guidance on every 
nuance. We will revisit the guidance in 2020, but will also conduct 6 monthly audits, in order to 
monitor its effects, and will introduce new guidance as appropriate.  
 
In summary, this update describes a modified approach to concerns that have arisen from our 
experiences following the publication in 2015 of our design and analysis guidelines. The areas of 
focus have been selected from our internal audits as issues requiring reconsideration and aspects of 
experimentation that we did not consider in the first iteration. We will continue to use this 
approach of internal audit and reappraisal to assess and to ensure that BJP committed to 
encouraging good experimental practice. Our intention is to continue to support the Pharmacology 
community in identifying strategies that support and enable transparency and reproducibility. As 
we stated previously (Curtis et al 2015) some of our guidance is arbitrary, and some will change. We 
will make progress, but it will need clear requirements and constant vigilance with progress made 
in stages. This is our stage II. 
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